Table 2. Analysis of subgroups in vaccine-associated menstrual disorders adverse events disproportionality

	Total	Vaccine-associated menstrual disorders			IC (IC0.25) based on age, years
		Observed	ROR (95% CI)	IC (IC0.25)	0-11	12-17	18-44	45-64	≥65
Total	4,939,712	147,158	27.76 (27.53 - 27.99)	3.42 (3.41)	1.10 (0.85)	2.14 (2.08)	2.83 (2.82)	3.85 (3.83)	3.07 (2.79)
Vaccine types
Anthrax vaccines	2,586	22	2.82 (1.85 - 4.29)	1.43 (0.72)	N/A	N/A	0.26 (-0.46)	N/A	N/A
Cholera vaccines	1,427	1	0.23 (0.03 - 1.64)	-1.69 (-5.47)	N/A	N/A	N/A	0.80 (-2.98)	N/A
DTaP-IPV-Hib vaccines	389,638	99	0.08 (0.07 - 0.10)	-3.57 (-3.90)	-2.57 (-3.98)	-1.58 (-2.25)	-2.41 (-2.86)	-2.21 (-3.77)	N/A
Meningococcal vaccines	74,411	57	0.25 (0.19 - 0.33)	-1.98 (-2.42)	-0.34 (-2.11)	-1.37 (-1.92)	-2.51 (-3.49)	N/A	N/A
Pneumococcal vaccines	146,717	8	0.02 (0.01 - 0.04)	-5.71 (-6.92)	-2.61 (-6.40)	N/A	N/A	-2.17 (-3.94)	N/A
Tuberculosis vaccines	14,484	1	0.02 (0.00 - 0.16)	-4.89 (-8.67)	N/A	N/A	-2.05 (-5.83)	N/A	N/A
Typhoid vaccines	8,637	21	0.80 (0.52 - 1.23)	-0.31 (-1.04)	N/A	-0.69 (-4.48)	-1.04 (-1.85)	0.10 (-2.49)	N/A
Encephalitis vaccines	10,549	21	0.66 (0.43 - 1.01)	-0.60 (-1.33)	N/A	1.67 (0.59)	-2.19 (-3.60)	1.00 (-0.56)	N/A
Influenza vaccines	238,538	148	0.20 (0.17 - 0.24)	-2.29 (-2.56)	-1.49 (-5.27)	-0.71 (-1.39)	-2.63 (-2.98)	-1.56 (-2.23)	-0.30 (-4.08)
Hepatitis A vaccines	32,098	70	0.72 (0.57 - 0.91)	-0.47 (-0.87)	0.29 (-2.30)	-0.26 (-1.10)	-0.92 (-1.47)	0.07 (-1.49)	N/A
Hepatitis B vaccines	62,822	80	0.42 (0.34 - 0.52)	-1.25 (-1.62)	-0.15 (-2.75)	-1.41 (-2.49)	-2.15 (-2.65)	-0.24 (-1.46)	N/A
MMR vaccines	109,738	32	0.10 (0.07 - 0.14)	-3.36 (-3.95)	N/A	-1.06 (-2.04)	-2.82 (-3.61)	-0.73 (-3.32)	N/A
Rotavirus diarrhea vaccines	35,337	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Varicella-zoster vaccines	123,608	29	0.08 (0.05 - 0.11)	-3.67 (-4.29)	N/A	-0.75 (-1.69)	-2.30 (-3.24)	-4.57 (-8.35)	N/A
Papillomavirus vaccines	110,601	2,070	6.32 (6.05 - 6.60)	2.62 (2.55)	5.46 (5.11)	2.16 (2.07)	1.22 (1.06)	3.28 (2.26)	N/A
COVID-19 mRNA vaccines	2,658,719	129,010	49.51 (48.91 - 50.13)	3.36 (3.35)	4.54 (4.15)	3.02 (2.96)	3.31 (3.30)	4.30 (4.28)	3.41 (3.09)
Ad5-vectored COVID-19 vaccines	800,138	15,325	4.44 (4.36 - 4.51)	2.02 (1.99)	3.28 (1.87)	0.88 (-0.02)	1.81 (1.78)	3.27 (3.21)	3.33 (2.72)
Inactivated whole-virus COVID-19 vaccines	90,197	94	0.22 (0.18 - 0.27)	-2.18 (-2.52)	N/A	-1.43 (-5.21)	-2.68 (-3.08)	-0.50 (-1.25)	N/A
Others*	29,467	70	0.78 (0.62 - 0.99)	-0.35 (-0.75)	N/A	-2.49 (-6.27)	-1.96 (-2.55)	-0.50 (-2.27)	N/A

Abbreviations: CI, confidence interval; DTaP-IPV-Hib, diphtheria, tetanus toxoids, pertussis, polio, and Hemophilus influenza type b; IC, information component; MMR, measles, mumps, and rubella; ROR, reported odds ratio.
Bold style indicates when the value of IC_0.25 is greater than 0.0 or the lower end of the ROR 95% CI is greater than 1.0. This means it is statistically significant.
Numbers in bold indicate a statistical significance.
Others included brucellosis, dengue vaccines, Ebola, leptospirosis, plague, rabies, smallpox, tuberculosis, typhus, and yellow fever vaccines.